QuickView for Altretamine (compound)

645-05-6; SPBio_003071; Lopac-A-8723; ZINC00000905; Spectrum3_000951; NCGC00015100-01; NCGC00015100-02; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; Altretaminum [INN-Latin]; KB-913.
show more »

645-05-6; SPBio_003071; Lopac-A-8723; ZINC00000905; Spectrum3_000951; NCGC00015100-01; NCGC00015100-02; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; Altretaminum [INN-Latin]; KB-913; KBio2_004356; 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'',N''-hexamethyl-; Spectrum_001308; Altretamine; s-Triazine, 2,4,6-tris(dimethylamino)-; CCRIS 5492; 4-26-00-01256 (Beilstein Handbook Reference); AIDS124133; SMR000058181; CAS-654-05-6; AI3-50852; Spectrum4_001064; Altretamine (USP); N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; DivK1c_000772; NSC 13875; Hemel; EU-0100083; AIDS-124133; BRN 0195058; NSC13875; KBio3_002042; HXM; 2,4,6-Tris(dimethylamino)-s-triazine; HTM; NINDS_000772; KBio2_001788; EINECS 211-428-4; KBioSS_001788; Prestwick0_000946; Hexalen (TN); Altretamina [INN-Spanish]; KBio1_000772; Prestwick1_000946; KBioGR_001388; Spectrum2_000907; Hexastat; MLS000069621; HMM; D02841; A0567/0026158; Hexalen; ENT 50852; KBio2_006924; Hexamethylmelamine; NSC-13875; NCI60_000871; NC 195; NCI-C50259; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; ChemDiv2_005185; 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'', N''-hexamethyl-; Melamine, hexamethyl-; Altretamine [USAN:BAN:INN]; SPBio_000754
show less «

HTM; HEXAMETHYLMELAMINE; Altretaminum [INN-Latin]; HMM; HXM

Altretamine is a novel antineoplastic agent. The precise mechanism by which altretamine exerts its cytotoxic effect is unknown, although a number of theoretical possibilities have been studied. Structurally, altretamine resembles the alkylating agent triethylenemelamine, yet in vitro tests for alkylating activity of altretamine and its metab...
show more »

Altretamine is a novel antineoplastic agent. The precise mechanism by which altretamine exerts its cytotoxic effect is unknown, although a number of theoretical possibilities have been studied. Structurally, altretamine resembles the alkylating agent triethylenemelamine, yet in vitro tests for alkylating activity of altretamine and its metabolitics have been negative. Altretamine has been demonstrated to be efficacious for certain ovarian tumors resistant to classical alkylating agents. Metabolism of altretamine is a requirement of cytotoxicity. Synthetic monohydroxymethylmelamines, and products of altretamine metabolism, in vitro and in vivo, can form covalent adducts with tissue macromolecules including DNA, but the relevance of these reactions to antitumor activity is unknown.
show less «